Amy Delderfield/LinkedIn
Mar 28, 2026, 18:41
Amy Delderfield: One Trial, Big Implications for Anticoagulant Choice
Amy Delderfield, Founder of Medicine Central, STEM Advisor to the UN, shared a post on LinkedIn:
“3.3 percent versus 7.1 percent…
That’s the bleeding rate in the first ever randomized head-to-head comparison of apixaban vs rivaroxaban for VTE.
RR 0.46 (95 percent CI 0.33 to 0.65; P<0.001).
For over a decade we’ve treated them as interchangeable.
The COBRRA trial, just published in the NEJM, suggests they’re not.
- 2,760 patients.
- 54 percent relative risk reduction in clinically relevant bleeding with apixaban.
- No difference in clot recurrence.
Could it be down to the dosing?
Rivaroxaban’s loading phase is longer and higher.
One trial.
But a big one.
Concise breakdown and what is means for primary care clinicians here.
Intended for Healthcare Professionals.”
Stay updated with Hemostasis Today.
-
Mar 28, 2026, 19:04Roberta Gualtierotti: High Engagement for Research on Non-Replacement Therapies in Hemophilia
-
Mar 28, 2026, 19:02Marking a Century of Progress in von Willebrand Disease – HFA
-
Mar 28, 2026, 18:57Jim Hoffman: NETosis Dysregulation Links Cancer Progression and Autoimmunity
-
Mar 28, 2026, 18:55Ifeanyichukwu Ifechidere: Which Coagulation Factors Are Not Involved in Bleeding?
-
Mar 28, 2026, 18:54Examining Critical Gaps in AF Stroke Prevention – JTH
-
Mar 28, 2026, 18:52Simon Senanu: Key Laboratory Markers of Hemolytic Anemia
-
Mar 28, 2026, 18:51Asad Ikram: Headache and Visual Impairment in Idiopathic Intracranial Hypertension
-
Mar 28, 2026, 18:48Abdul Mannan: How SSRIs Might Affect Platelet Function
-
Mar 28, 2026, 18:47Cedric Hermans: A Useful Platform for Daily Practice in Hemostasis